CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), targeting programmed death-ligand 1 (PD-L1) or programmed death 1 (PD-1), have been found to be associated with improved overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) [1,2,3].